Genelife Clinical Research Pvt. Ltd.

25/08/2026

The pharmaceutical industry's best new drugs may already exist.
Sildenafil was a cardiovascular compound before it became a treatment for erectile dysfunction and pulmonary arterial hypertension. Thalidomide was a sedative before it became foundational in multiple myeloma treatment. Nitisinone was developed as a herbicide before it received FDA approval in 2025 as the first targeted therapy for alkaptonuria.
Drug repurposing — finding new therapeutic applications for existing compounds — is not a niche strategy. It is one of the most scientifically rigorous and commercially intelligent approaches to drug development available. The molecule's safety profile is known. The manufacturing process exists. The pharmacokinetic behavior in humans is established.
What remains to be done — proving efficacy in the new indication, establishing the appropriate dose, characterizing safety in the new patient population, navigating the regulatory pathway — is substantial. But it starts from a place of greater biological knowledge than any new molecular entity can offer.
We've written a detailed breakdown of drug repurposing as a clinical development strategy — what AI is doing to accelerate candidate identification, what the clinical development program for a repurposed drug actually requires, and why India is an increasingly strategic location for repurposing proof-of-concept studies.

Genelife, Clinical Research, GCP, Medical Device, Patient Recruitment, Asthma, Oncology, Ophthalmology, Clinical Trials, Cancer, tuberculosis

23/08/2026

What AI did in Rentosertib's development:
→ Identified TNIK as a novel IPF target in months, not years → Generated and optimized the molecular structure → Compressed discovery from 4–6 years to 18 months
What AI did not do:
→ Design the double-blind, placebo-controlled Phase IIa trial → Select forced vital capacity as the primary endpoint → Manage 22 investigational sites across China → Generate the Nature Medicine publication → Navigate the regulatory pathway to Phase III
The Phase IIa result — +98.4 mL lung function improvement vs −20.3 mL decline in placebo — was not an AI output. It was rigorous clinical methodology applied correctly.
That's the part of the AI-in-pharma story that isn't being told clearly enough.

Genelife, Clinical Research, GCP, Medical Device, Patient Recruitment, Asthma, Oncology, Ophthalmology, Clinical Trials, Cancer, tuberculosis

18/08/2026

In July 2026, Insilico Medicine initiated a Phase III clinical trial for Rentosertib — a drug whose target was identified by AI, whose molecular structure was generated by generative AI, and which has now progressed to a 320-patient pivotal trial for idiopathic pulmonary fibrosis.
It is the first drug designed by AI to reach late-stage clinical development. And it deserves neither uncritical celebration nor reflexive dismissal.
What it deserves is a clear-eyed look at what AI actually contributed — and what it didn't.
AI compressed the discovery timeline from 4–6 years to 18 months. It identified TNIK as a novel target that human researchers had deprioritized. It generated and optimized the molecular structure.
What AI did not do: design the Phase IIa trial. Select the endpoint. Calculate the sample size. Manage 22 investigational sites. Collect and validate the clinical data. Write the Nature Medicine publication. Navigate the regulatory submissions.
Every one of those was human expertise — clinical scientists, biostatisticians, regulatory specialists, and investigative sites applying the same rigorous methodology that has governed clinical research for decades.
Rentosertib's Phase IIa result — patients receiving 60mg once-daily showed a mean lung function improvement of +98.4 mL, versus a decline of −20.3 mL in the placebo group — was not an AI output. It was the result of a double-blind, placebo-controlled randomized trial conducted correctly.
That distinction matters more than almost anything else being said about AI and drug development right now.
We've written a detailed analysis of what Rentosertib's Phase III initiation actually means — for AI-driven discovery, for clinical development, and for the sponsors and CROs who will execute these programs.

15/08/2026

Wishing you a Happy Independence Day! 🇮🇳
On this proud occasion of India's 80th Independence Day, Team Genelife Clinical Research extends warm wishes to every Indian — at home and across the world.
India's freedom was won through courage, sacrifice, and an unshakeable belief in a better future. That same spirit drives us every day in clinical research — advancing science, ensuring safety, and working toward a healthier India.
As a proud Indian CRO, we remain committed to:
🔬 Bringing global clinical research to India
🧬 Developing therapies for Indian patients
💊 Contributing to India's growing role in global drug development
Jai Hind! 🇮🇳
Genelife Clinical Research Pvt. Ltd.
Advancing Science · Serving India

07/08/2026

There is a sentence that has ended more nutraceutical businesses than any reformulation or supply chain failure.
It usually reads something like: "Clinically proven to treat joint inflammation."
Or: "Reduces blood sugar in diabetic patients."
Or: "Prevents cold and flu."
Each of these crosses the same line — from a permissible nutraceutical claim into therapeutic drug territory. When that line is crossed, the product is no longer a nutraceutical. It is, in regulatory terms, an unapproved drug. In India that means CDSCO jurisdiction. In the US it means FDA's drug division. The consequences — recall, license suspension, prosecution — are not proportionate to what was often a careless word choice rather than deliberate deception.
Understanding the four categories of nutraceutical health claims — nutrient content, structure/function, health claims, and general wellbeing — and precisely where the boundaries between them lie is not a compliance exercise. It is a commercial survival skill.
We have written a detailed guide to the claim categories and substantiation procedures across India (FSSAI), the US (FDA and FTC), and the EU (EFSA) — including the specific procedural steps, documentation requirements, and the practical checklist every manufacturer needs before a claim goes on the pack.

Every nutraceutical product lives and dies by what it claims. "Supports heart health.

04/08/2026

National Nutrition Week is a good moment to ask a question the nutraceutical industry doesn't ask often enough:

How much of what we sell as "nutritional innovation" is actually supported by clinical evidence?

The honest answer is: not enough. Most nutraceutical health claims rest on ingredient plausibility, in-vitro data, or studies conducted in populations that don't reflect the consumer buying the product. The gap between what brands claim and what the evidence actually demonstrates is wide — and regulators, retail buyers, and increasingly, consumers are beginning to close it.

At Genelife, this is the gap we work in — helping nutraceutical, botanical, and functional food companies generate the clinical evidence that turns nutritional science into defensible, credible health claims.

Nutrition matters too much to be left unsubstantiated.

02/08/2026

This week is World Breastfeeding Week — and it is a good moment to acknowledge something the clinical research community does not discuss often enough.

The science behind breastfeeding is still evolving. Human milk science, maternal nutrition, neonatal microbiome development, the immunological properties of colostrum — these are active areas of clinical research with significant evidence gaps that directly affect how millions of mothers and newborns are supported around the world.

At Genelife, we work across maternal health, neonatal care, nutraceutical clinical evidence, and women's health research. The intersection of good science and early-life health outcomes is one of the most important frontiers in clinical research — and one where the evidence base still has a long way to go.

To every mother navigating those first weeks with a newborn: the science is on your side, and more of it is being built every day.

'sHealth

01/08/2026

On World Lung Cancer Day, one statistic stands out above all others:

kills more people globally each year than colon, breast, and prostate cancer combined.

And yet it remains one of the most underfunded and stigmatised cancers — partly because of the persistent assumption that it only affects smokers. It doesn't. Non-smokers account for a significant share of diagnoses, linked to radon exposure, air pollution, secondhand smoke, and genetic factors that have nothing to do with ci******es.

The single most impactful weapon we have is early detection. When caught early, survival rates improve dramatically. When caught late — as most cases still are — options narrow significantly.

At Genelife Clinical Research, we are proud to support oncology clinical research that brings better diagnostics and treatments to patients who need them. Every clinical trial we support is a step toward better outcomes for real people living with this disease.

To everyone affected by lung cancer — patients, families, caregivers, and researchers — today is for you.

31/07/2026

At Genelife Clinical Research, we help companies generate scientifically credible evidence through GCP-compliant clinical studies designed for global regulatory and commercial requirements.
Our capabilities include:
✔ HRIPT (Human Repeat Insult Patch Test)
✔ Dermatological & Skin Safety Testing
✔ SPF & UVA Testing
✔ Anti-ageing & Skin Rejuvenation Studies
✔ Moisturisation & Skin Barrier Assessment
✔ Skin Brightening & Pigmentation Studies
✔ Hair & Scalp Clinical Evaluation
✔ Vaginal Microbiome & qPCR Studies
✔ Gynaecologist-Supervised Intimate Care Testing
✔ Marketing Claim Substantiation & Clinical Study Reports
Whether you are developing innovative skincare formulations, botanical cosmetics, intimate hygiene products, or advanced cosmeceuticals, scientifically validated clinical evidence helps build regulatory confidence, retailer acceptance, and consumer trust.

What Is Cosmeceutical Clinical Testing? Cosmeceutical clinical testing is the systematic generation of clinical evidence to substantiate the safety and efficacy claims made on cosmetic, personal care, and intimate hygiene products. It encompasses a range of study types — from dermatologist-supervi...

31/07/2026

On Monday we published an article on clinical evidence for cosmeceutical claims.
The point that surprised most people we've shared it with:
"Microbiome-friendly" is now one of the most common claims in skin care and intimate care — and one of the most poorly substantiated.
In vitro bacterial culture studies showing that a product doesn't kill Lactobacillus in a petri dish are not microbiome evidence. They are laboratory bench tests that tell you almost nothing about what happens to the actual microbiome of an actual person using the product under real-world conditions.
Genuine microbiome claim substantiation requires 16S rRNA sequencing or qPCR-based assessment of microbiome composition in human subjects — before and after product use, in adequate sample sizes, with appropriate statistical analysis.
The gap between what most "microbiome-friendly" brands have as evidence and what the claim actually requires is wide. And it is exactly that gap that creates the opportunity for brands who take the science seriously.